Is the incidence of nasopharyngeal (NP) cancer increasing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nasopharyngeal Cancer Incidence is Declining, Not Increasing

No, the incidence of nasopharyngeal carcinoma (NPC) is not increasing—it has been declining worldwide over recent decades. 1

Global Incidence Trends

The most authoritative data from the ESMO-EURACAN guidelines clearly demonstrates that in recent decades (1970-2007), the incidence of NPC has declined worldwide, with substantial reductions in South and East Asia, North America and the Nordic countries. 1 This represents a consistent downward trend across multiple geographic regions over nearly four decades.

More recent epidemiological analysis confirms this pattern, noting that incidence has declined gradually but progressively in the past decade, and mortality has been reduced substantially. 2 These improvements likely reflect lifestyle and environmental changes, enhanced understanding of pathogenesis and risk factors, and population screening initiatives. 2

Current Geographic Distribution

Despite the declining trend, NPC maintains distinct geographic patterns: 1

  • Highest rates: East and Southeast Asia with age-standardized incidence rates (ASIRs) of 7 per 100,000 in Singapore, the Maldives, and Indonesia; 6 per 100,000 in Malaysia and Vietnam; 3 per 100,000 in China 1
  • Europe: ASIR of 0.4 per 100,000, with approximately 5,000 new cases annually 1
  • Global: Approximately 129,000 new cases reported in 2018 1

The male-to-female incidence ratio remains 2.75:1. 1

Clinical Implications

The declining incidence should not diminish vigilance, particularly in high-risk populations including individuals of Southern Chinese, Southeast Asian, Arctic, or Middle Eastern/North African descent. 3 Key risk factors remain: elevated Epstein-Barr virus antibody titers, consumption of salt-preserved fish, family history of NPC, and certain HLA class I genotypes. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nasopharyngeal carcinoma.

Lancet (London, England), 2019

Research

The enigmatic epidemiology of nasopharyngeal carcinoma.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.